Latest news with #Nim
Forbes
3 days ago
- Business
- Forbes
Nvidia Announces Massive New Initiatives in Pharma And Clinical Research
Nvidia has quickly become a leader in the AI ecosystem. Founder and CEO of Nvidia, Jensen Huang, announced today in his GTC Paris keynote that the company has inked two new large partnerships to advance the company's work in healthcare and life-sciences. The first is with European based global pharmaceutical giant, Novo Nordisk, to advance drug discovery and development efforts by leveraging an existing partnership with the Danish Centre for AI Innovation's (DCAI) Gefion AI supercomputer. Novo Nordisk will utilize Gefion and a variety of Nvidia platforms such as BioNeMo, Nim, and Omniverse to build and develop customized AI models, foster agentic AI workflows and even create simulation and digital twin environments to advance physical AI applications. The primary goal will be to use these tools to better understand potential drug candidates and structures in order to build molecular models that can further the drug discovery and development pipeline. Rory Kelleher, senior director of business development for life sciences at Nvidia, explains that drug discovery can claim massive benefits from generative AI, especially in the R&D space. Mishal Patel, senior vice president of AI and digital innovation at Novo Nordisk, comments that the combination of Gefion and Nvidia's computing platforms is an unprecedented approach and will enable the building of custom models that can truly empower better efficiency and efficacy. More generally, Gefion is a computational behemoth and has been used by numerous enterprises to advance their computing capabilities; for example, Danish startup Teton has been working with Nvidia and Gefion to build out an AI care companion for clinical settings. The second partnership that Nvidia announced today is with IQVIA to advance the use of AI agents in the clinical research and commercialization spaces. The companies will collaborate to launch multiple AI powered agents to accelerate pharmaceutical development workflows for biotech and medical device customers globally. Importantly, the new agents will be 'orchestrator agents,' meaning that they will act as supervisors for groups of 'sub-agents' that each have their own specialties; the supervising agent will route a received task to the appropriate sub-agent, enabling an efficient and automated workflow. Using this technology, IQVIA is hoping to tackle some of the hardest problems in the drug development and pharmaceutical workflows. For example, clinical trials often require a significant amount of work to launch and execute. Agents can help identify targets, develop a knowledge base using existing research databases and even review clinical data to better understand insights and automate the review process. Avinob Roy, vice president and general manager at IQVIA, explains that AI agents will transform the entire 'molecule to market' lifecycle. Overall, the news comes at a time when Nvidia's reach into the AI ecosystem has been incredibly impactful. The company indicated in its latest quarterly report a continuing surge in demand for its GPUs and hardware ecosystem. Though most traditionally a hardware giant, it has also increasingly diversified its work into the cloud and software ecosystems, furthering its moat in the AI space. Undoubtedly, there is stiff competition in the AI race. With regard to hardware alone, technology giants such as Google and Amazon depend heavily on Nvidia for its GPUs; however, the companies are also rapidly developing their own silicon products, such as Google's work with tensor processing units (TPUs) and Amazon's customized silicon products (i.e., Trainium, Graviton and Inferentia). With regard to healthcare and life-sciences more broadly, all of the large technology hyperscalers are investing billions of dollars in these fields. For example, one of the most prominent success stories is Alphabet's Isomorphic Labs and its work with drug development models. Companies like Microsoft are also rolling out new enterprise grade tools and infrastructure capabilities to empower traditional life-science companies. Indeed, the innovation is rapid and unprecedented. Despite the perception of a 'competition' however, there is no need for a clear cut winner. The reality of this progress across the entire spectrum of technology companies is that ultimately, both the healthcare and life-sciences industries stand to gain immense benefits.
Irish Times
10-05-2025
- Entertainment
- Irish Times
Gunk by Saba Sams: An elusive, idiosyncratic book
'Do I flatten you?' the narrator of Gunk asks the woman bearing her child. At this point of the novel I answered internally: yes. Nineteen-year-old Nim has agreed to see through a pregnancy caused by a one-night stand and then give the baby to the older, divorced protagonist, Jules: 'I just think: you want a baby and I've got one. It makes sense.' It doesn't, and the narrator's acknowledgement ('It makes no sense at all') does nothing to offset this reader's early scepticism. But we're building towards a deeper, more plausible motive – one I won't spoil. Sams knows what she's about in making Nim's rationale so hard to swallow. It creates suspense we must keep reading to resolve. Behind these women there's a man in the background: Leon. Jules divorced him five years ago after he cheated on her constantly with the students frequenting his dive bar. He is the father of Nim's child, at least biologically. There are no mysteries surrounding Leon. We understand how society has enabled his narcissism: 'The whole world was kind to men. The whole world spoiled them.' His psyche lends itself to one-line summaries: 'He'd take any pity, any disgust, so long as his name was on another's lips.' READ MORE The women's personalities emerge more slowly, largely through how they relate to others. We intuit that Jules must have charisma from how others throw themselves at her, though she remains oblivious to her powers. Nim comes to us first through awed descriptions of how well she does her job at the bar, and we patch together her complexity through a series of vulnerable confessions. Those used to being tiptoed around often prove easier to pin down. It took me longer to feel I had a grasp on the women, but this reflects the subtlety with which they must operate compared with Leon. The prose grew on me, too. There are rough edges – long successions of sentences beginning with 'I', unvaried repetition of details such as Nim's shaved head or the height difference between her and Leon – but they suit the narrator's unfurnished inner life. She's not speaking to impress but to witness. Gunk is an elusive, idiosyncratic book that I would not want to have been written any differently. It deals in relationships that literary conventions were not built to hold. 'There's no format for this, so we have no choice but to make it up', concludes the narrator. I wish Jules and Nim the best of luck.
Reuters
04-04-2025
- Business
- Reuters
India rupee climbs past 85/USD, central bank inaction surprises
MUMBAI, April 4 (Reuters) - The Reserve Bank of India's inaction to the rupee's ongoing rally, which lifted it above 85, surprised market participants and sent traders scrambling to adjust positions after the central bank did not step in to absorb dollars as was expected. The rupee rose to a peak of 84.9675 in early trade on Friday before trimming gains and was last quoted at 85.2650, up 0.2% on the day. Recession worries stoked by sweeping U.S. tariffs dragged the dollar, helping the rupee rise above 85 for the first time this year and extending its rally into April after seasonal and portfolio dollar inflows boosted it last month. Traders have pointed out that while the RBI would routinely intervene to buy dollars during periods of rupee strength last year, the central bank appears to have held off this time even as the rupee climbed more than 2.5% in around three weeks. The RBI did not immediately respond to a request seeking comment. The currency's surprising rally has also prompted a sharp unwinding of short bets against the currency, per a Reuters poll. The rupee's recent gains are in line with its Asian peers and the RBI allowing that opens up room for a more expansionary monetary policy to support growth, said Dhiraj Nim, an economist and FX rates strategist at ANZ. The valuation gains accruing to FX reserves have also turned positive, reducing the urgency to buy dollars and preventing India's FX policy from drawing attention while a trade deal with the U.S. is being negotiated, Nim said. Expectations of sharper policy easing by the RBI have increased amid concerns about India's growth outlook being hurt by U.S. tariffs. Citi and Goldman Sachs both raised their expected quantum of rate cuts by the RBI this year. However, that has done little to dent the rupee's stride in the face of a weaker dollar, even as traders and analysts caution that the global growth shock of U.S. tariffs is bound to lead the rupee lower alongside its regional peers. Barclays currently recommends taking a long position on the 3-month dollar-rupee non-deliverable forward with a target of 90. The 3-month NDF was last quoted at around 85.75.
